2nd Quarter - Report
US ONCOLOGY for US ONCOLOGY
Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 1392/S 1221 - Legislation to ensure payment amounts for drugs and biologicals under Medicare Part B HR 2939 - Legislation to create a Medicare Oncology Pilot Program HR 3200 - House Healthcare Reform Bill
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATT BROW | — |
| GEOFF WERTH | — |
Medicare/Medicaid MMM
HR 1392/S 1221 - Legislation to ensure payment amounts for drugs and biologicals under Medicare Part B HR 2939 - Legislation to create a Medicare Oncology Pilot Program HR 3200 - House Healthcare Reform Bill
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATT BROW | — |
| GEOFF WERTH | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.